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SUMMARY
Objective: To investigate the effect of healthcare provider (HCP) type (primary vs.
specialist) on glycaemic control and other treatment parameters. Research
design and methods: Study of Once-Daily Levemir (SOLVETM) is an international,
24-week, observational study of insulin initiation in people with type 2 diabetes.
Results: A total of 17,374 subjects were included, comprising 4144 (23.9%) pri-
mary care subjects. Glycaemic control improved in both HCP groups from baseline
to final visit [glycated haemoglobin (HbA1c) 1.2  1.4% (13.1  15.3 mmol/
mol) and 1.3  1.6% (14.2  17.5 mmol/mol), respectively]. After adjust-
ment for known confounders, there was no statistically significant effect of HCP
group on final HbA1c [0.04%, 95% confidence interval (CI) 0.09 to 0.01
(0.4 mmol/mol, 95% CI 1.00.1 mmol/mol), p = 0.1590]. However, insulin
doses at the final visit were higher in primary care patients (+0.06, 95% CI 0.06–
0.07 U/kg, p < 0.0001). Logistic regression demonstrated a significant effect of
HCP type (primary vs. specialist care) on hypoglycaemia risk [odds ratio (OR) 0.75,
95% CI 0.64–0.87, p = 0.0002]. Primary care physicians took more time to train
patients and had more frequent contact with patients than specialists (both
p < 0.0001). Conclusions: Primary care physicians and specialists achieved
comparable improvements in glycaemic control following insulin initiation.
What’s known
• Subjects with type 2 diabetes are being
increasingly managed in primary care as opposed
to specialist care. The impact on mortality, risk
factor control and resource use between these
two types of care is continuously under
assessment.
• Primary care physicians often have concerns
regarding the unfamiliarity and the resources
required when initiating insulin therapy.
What’s new
• From a large, international, observational cohort,
this analysis shows that primary and specialist
care achieved comparable improvements in
HbA1c in subjects with type 2 diabetes who
initiated and maintained treatment with basal
insulin for 24 weeks.
• Differences were reported between primary and
specialist care in terms of insulin dose, the risk
of hypoglycaemia, and resource utilisation.
• The findings provide reassurance for primary care
management of subjects with type 2 diabetes.
Introduction
Type 2 diabetes care is increasingly managed in pri-
mary care (1). The high and increasing prevalence of
type 2 diabetes and the strain on limited specialist
resources determine the involvement of primary care
(2). This transition to primary care has not been
without controversy, and the impact on mortality,
risk factor control (including glycaemic control,
blood pressure, lipid control and weight manage-
ment) (3), processes [such as frequency of glycated
haemoglobin (HbA1c) testing, initiation of risk fac-
tor preventative therapy] (4) and resource use (5,6)
have been scrutinised. However, primary-based struc-
tured care can achieve the quality of care comparable
with international best practice standards, despite
limited investment (7).
Regimen adherence is known to be poor in
chronic medical conditions, such as type 2
diabetes, and for self-care behaviours like diet and
exercise (8). Improved accessibility to physicians
(e.g. through primary care services) might be
expected to encourage greater therapy adherence,
and there is a greater opportunity for therapeutic
intervention, monitoring and titration (3,6,9,10). In
addition, implementation of patient-driven insulin
treatment algorithms in primary care may be easier
with the improved safety profiles of basal insulin
analogues (11). However, primary care physicians
often have concerns about the resources required
and unfamiliarity with initiating insulin therapy
(6).
In this study, the demography, therapeutic
management and outcomes of patients managed by
primary and specialist care practitioners during insu-
lin initiation are described and compared, using data
collected from a large, international observational
study.
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Research design and methods
The Study of Once-Daily Levemir (SOLVETM) is a
large, international, non-interventional study that
enrolled and prospectively followed people with type
2 diabetes who were under primary care and special-
ist care. The study was conducted in 10 countries:
Canada, China, Germany, Israel, Italy, Poland, Portu-
gal, Spain, Turkey and the UK. The study was pre-
registered with ClinicalTrials.gov (NCT00825643 and
NCT00740519) and was approved by local ethics
committees in each of the participating countries.
Details of the study methodology have been
reported previously (12). Patients were eligible for
study inclusion if they were > 18 years of age, had a
diagnosis of type 2 diabetes, and a decision had
already been made to initiate insulin using once-daily
insulin detemir. Other inclusion criteria differed
between countries because of local regulatory and
ethics requirements, which were described previously
(12). Subjects were excluded if they became pregnant
or were intending to become pregnant, deviated
from the once-daily insulin regimen using more fre-
quent basal insulin administration or added bolus
insulin. Data were collected from case notes and
measurements were made as close as possible to
three time points: immediately prior to insulin initia-
tion (preinsulin) and at 12- and 24-week follow-ups.
The primary study endpoint was the incidence of
severe adverse drug reactions and/or severe hypogly-
caemia. Secondary endpoints also included measure-
ments of glycaemic efficacy (e.g. HbA1c), safety (e.g.
minor hypoglycaemia and weight) and health
resource use. Severe hypoglycaemia was defined as a
hypoglycaemic event requiring third-party assistance,
and minor hypoglycaemia was defined as measured
blood glucose ≤ 3.9 mmol/l (≤ 56 mg/dl), with or
without symptoms.
The study had no prescribed procedures, and all
management decisions were entirely at the discretion
of the treating healthcare provider (HCP). In the
UK, HCPs included specialist diabetes nurses. In all
other countries, care was provided by primary or
specialist care physicians.
Statistical analysis
Continuous data are presented as the mean with
standard deviation, and categorical data are pre-
sented as the frequency and percentage. Baseline
group comparisons were made using an unpaired t-
test and chi-square analyses for continuous and
categorical data, respectively. HbA1c values were
converted from Diabetes Control and Complications
Trial-derived to International Federation of Clinical
Chemistry recommended units (13).
Because this was a non-randomised study, regres-
sion models were used to describe the effect of
patients being managed in primary vs. specialist care,
adjusting for several previously identified con-
founders. Models of HbA1c at the final visit and the
odds of at least one hypoglycaemic episode (mild or
severe) included the following parameters: age cate-
gory (< 50 years, 50–75 years in 5-year intervals and
≥ 75 years), diabetes duration (in quartiles), body
mass index (BMI) category (< 25 kg/m2, 25 to
< 30 kg/m2, 30 to < 35 kg/m2 and ≥ 35 kg/m2),
previous history of hypoglycaemia or microvascular
disease, number and change in oral antidiabetic drug
(OAD) therapy at the time of insulin initiation,
HbA1c at baseline and insulin dose (U in quartiles).
The odds of weight loss ≥ 1 kg included the follow-
ing parameters: sex, BMI (categories as described
above), number of OADs at baseline and baseline
HbA1c. The model of insulin dose at the final visit
included adjustment for duration of diabetes and
weight at baseline. These regression models have
been described previously (14,15). All regression
models included the additional variable, HCP type,
to denote treatment by a primary or specialist care
physician.
Missing data were not imputed and the level of
significance was set at a = 0.05. All analyses were
performed using Statistical Analysis Software version
9.1 or newer (SAS Institute, Cary, NC, USA).
Results
A total of 17,374 subjects were included in the analy-
sis, comprising 4144 (23.9%) subjects managed in
primary care and 13,230 (76.1%) subjects managed
in specialist care (Table 1). Out of the five highest-
recruiting countries, an average of 12.6% of patients
were recruited from primary care, with four coun-
tries (Italy, China, Israel and Poland) not enrolling
any patients from primary care (Table S1).
Baseline characteristics
There were significant differences between the pri-
mary and specialist care cohorts at baseline
(Table 1). The primary care group of patients were
older, had a higher BMI and had a shorter history
of OAD treatment despite having a similar dura-
tion of diabetes compared with the specialist care
group. A larger proportion of patients managed
in primary care also had a previous history of
macrovascular disease and hypoglycaemia. The
overall incidence of hypoglycaemia prior to insulin
therapy was low, and glycaemic control was similar
between the primary and specialist care groups
(Table 1). A larger proportion of patients were
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managed using a single oral agent prior to insulin
initiation in the primary care group compared with
the specialist care group (39.5% vs. 26.9%,
p < 0.0001). The use of sulphonylureas, glinides, a-
glucosidase inhibitors and thiazolidinediones was
significantly lower in primary vs. specialist care,
with the largest difference being the sulphonylureas
(49.1% vs. 62.5%, respectively, p < 0.0001). The
use of metformin and dipeptidyl-peptidase IV
(DPP-IV) inhibitors was significantly higher in pri-
mary care, with 15.7% using DPP-IV inhibitors vs.
+ 3.6% in specialist care (p < 0.0001). A higher
proportion of patients managed in primary care
were also receiving lipid-lowering and antihyperten-
sive treatment (both p < 0.0001).
Glycaemic control, insulin doses, weight and
hypoglycaemia during the study
At baseline, the levels of HbA1c and fasting blood glu-
cose were similar between both groups (Table 1). After
24 weeks of treatment, there were significant improve-
ments in glycaemic control from baseline in both
primary and specialist care cohorts [change in
HbA1c 1.2  1.4% (13.1  15.3 mmol/mol) and
1.3  1.6% (14.2  17.5 mmol/mol), respec-
tively, both p < 0.001]. The change in fasting blood
glucose was 52  49 mg/dl (2.9  2.7 mmol/l)
and 56  54 mg/dl (3.1  3.0 mmol/l) in the pri-
mary and specialist groups, respectively] (Table 2).
Insulin doses increased from 13  7 U at baseline to
27  22 U at final visit in the group managed in pri-
Table 1 Baseline characteristics by healthcare provider group
Cohort
p valuePrimary care Specialist care
N (%) 4144 (23.9) 13,230 (76.1)
Age (years) 63.5  11.6 61.0  11.4 < 0.0001
Male (%) 2181 (52.7) 7008 (53.0) 0.7645
Ethnicity (%)
White 3018 (81.6) 9235 (72.0) < 0.0001
Black 73 (2.0) 44 (0.3)
Other 608 (16.4) 3546 (27.6)
Duration of diabetes (years) 9.5  6.6 9.8  7.2 0.1313
Duration of OAD treatment (years) 7.9  6.0 8.6  6.8 < 0.0001
Previous medical history (%)
Macrovascular complications 1211 (30.4) 3331 (25.5) < 0.0001
Microvascular complications 1310 (32.7) 4320 (33.0) 0.6688
Hypoglycaemia 229 (5.6) 620 (4.7) 0.0253
Severe hypoglycaemia (events ppy) 0.075  1.389 0.036  0.687 0.0436
Minor hypoglycaemia (events ppy) 2.429  26.450 1.332  13.211 0.0765
Weight (kg) 87.7  19.6 78.8  16.5 < 0.0001
BMI (kg/m2) 30.9  5.6 28.8  5.2 < 0.0001
FBG (mg/dl) [mmol/l] 187  54 [10.4  3.0] 186  56 [10.3  3.1] 0.2034
HbA1c (%) [mmol/mol] 8.9  1.6 [74.0  17.5] 8.9  1.6 (74.0  17.5) 0.7210
Number of OADs
1 1595 (39.5) 3505 (26.9) < 0.0001
2 1892 (46.9) 7352 (56.3)
> 2 547 (13.6) 2193 (16.8)
Types of OADs
Biguanide 3359 (83.3) 10,536 (80.7) 0.0003
Sulphonylureas 1980 (49.1) 8160 (62.5) < 0.0001
Glinides 483 (12.0) 2265 (17.4) < 0.0001
a-glucosidase inhibitors 149 (3.7) 1931 (14.8) < 0.0001
Thiazolidinediones 449 (11.1) 1626 (12.5) 0.0239
Dipeptidyl-peptidase IV inhibitors 633 (15.7) 474 (3.6) < 0.0001
Any lipid-lowering drug treatment 1866 (59.5) 4784 (40.2) < 0.0001
Any antihypertensive drug treatment 2634 (76.3) 7439 (58.7) < 0.0001
Continuous variables are given as mean  SD and categorical variables as number (%). BMI, body mass index; FBG, fasting blood
glucose; HbA1c, glycated haemoglobin; OAD, oral antidiabetic drug; ppy, per patient year; SD, standard deviation.
ª 2016 The Authors. International Journal of Clinical Practice Published by John Wiley & Sons Ltd.
Int J Clin Pract, March 2016, 70, 3, 236–243
238 Insulin initiation in primary and specialist care
mary care (p < 0.001) and from 13  6 to 20  12 U
in the group managed by specialist care (p < 0.001).
Patients from the primary care group had greater
weight at baseline compared with the specialist care
group (p < 0.0001, Table 1), but in both groups, there
was a mean weight reduction from baseline after
24 weeks of treatment (1.1  8.1 and 0.4  4.7
kg, respectively, both p < 0.001) (Table 2). At base-
line, patients from primary and specialist care groups
had different incidence rates of severe hypoglycaemia
(p = 0.0436) and similar rates of minor hypogly-
caemia (p = 0.0765) (Table 1). After 24 weeks of
treatment, the change relative to baseline in the inci-
dence of severe hypoglycaemia was 0.051 events per
patient year in the primary care group and 0.028
events per patient year in the specialist care group
(p < 0.001) (Table 2). The incidence of minor hypo-
glycaemia in patients managed in primary care was
similar to baseline (0.08 events per patient year,
p = 0.788), whereas the incidence of minor hypogly-
caemia increased from baseline in the group of
patients managed in specialist care (+0.36 events per
patient year, p < 0.001).
Table 3 shows the effect of HCP type on HbA1c
at the final visit, insulin dose at the final visit, the
odds of one or more episodes of hypoglycaemia
and the odds of weight loss ≥ 1 kg, following
adjustment for previously identified confounders.
The analyses show that there was no effect of HCP
type on the level of glycaemic control attained at
the final visit [HbA1c 0.04%, 95% confidence
interval (CI) 0.09 to 0.01 (0.4 mmol/mol, 95%
CI 1.0 to 0.1 mmol/mol), p = 0.1590 for primary
vs. specialist care]. Also, the odds of weight loss
≥ 1 kg were not statistically different in primary
care compared with specialist care [odds ratio (OR)
1.07, 95% CI 0.98–1.16, p = 0.1409]. Insulin doses,
however, were higher in patients managed in
primary care (+0.06, 95% CI 0.06–0.07 U/kg,
p < 0.0001), and logistic regression also demon-
strated a significant effect of HCP type on the risk
of hypoglycaemia. The odds of at least one hypogly-
caemic episode were lower in primary care
compared with specialist care (OR 0.75, 95% CI
0.64–0.87, p = 0.0002).
OAD management following insulin initiation
Insulin was most commonly used in combination
with a single oral agent for patients managed in
primary care, whereas for patients managed in
Table 2 Glycaemic control, weight, hypoglycaemia incidence and insulin dose by healthcare provider group after
24 weeks of treatment
Cohort
Primary care Specialist care
Glycaemic control
HbA1c (%) [mmol/mol]
Final visit 7.6  1.2 [60.0  13.1] 7.5  1.2 [58.0  13.1]
Change from baseline 1.2  1.4* [13.1  15.3] 1.3  1.6* [14.2  17.5]
FBG (mg/dl) [mmol/l]
Final visit 133  40 [7.4  2.2] 130  34 [7.2  1.9]
Change from baseline 52  49 [2.9  2.7] 56  54 [3.1  3.0]
Insulin dose (U)
Insulin initiation 13  7 13  6
Final visit 27  22 20  12
Change from baseline +14  22* +7  12*
Weight (kg)
Final visit 86.7  18.5 78.2  15.8
Change from baseline 1.1  8.1* 0.4  4.7*
Hypoglycaemia incidence (events ppy)
Severe hypoglycaemia
Final visit 0.027  0.947 0.005  0.224
Change from baseline 0.051 CI [0.108 to 0.005] 0.028* CI [0.040 to 0.015]
Hypoglycaemia incidence (events ppy)
Minor hypoglycaemia
Final visit 2.086  25.162 1.749  9.633
Change from baseline 0.083 CI [1.250 to 1.085] +0.362* CI [0.052–0.672]
FBG, fasting blood glucose; HbA1c, glycated haemoglobin; ppy, per patient year. *p < 0.001 for change from baseline.
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specialist care, most patients were prescribed insulin
in addition to at least two oral agents (p < 0.0001;
Table 4). In general, the proportion of patients
using each class of OAD decreased following the
addition of insulin, with the exception of metformin
and DPP-IV inhibitors (which remained similar to
baseline) in patients managed by primary care, and
glinides and a-glucosidase inhibitors (which
increased from baseline) in patients managed by
specialist care.
Physician resource utilisation
The majority of primary and specialist care physi-
cians felt confident about the patients’ ability to
self-inject and self-titrate the basal insulin dose
(91.8% and 95.7%, respectively) (Table S2). More
time was taken in primary care than in specialist
care to train patients to self-inject (18  16 min vs.
14  12 min, p < 0.0001), adjust doses (13 
13 min vs. 11  10 min, p < 0.0001) and for other
aspects of insulin treatment (22  26 min vs.
16  14 min, p < 0.0001). There was also evidence
of more frequent face-to-face contact with patients
in the group managed by primary care compared
with specialist care (3.0  2.5 vs. 1.7  2.0 office
contacts at the interim visit, respectively, and
2.3  2.3 vs. 1.4  1.7 office contacts at the final
visit, respectively; p < 0.0001). There were also a
Table 3 Effect of healthcare provider on HbA1c at final visit (%), insulin dose (U/kg), odds of at least one
hypoglycaemia event [odds ratio (OR)] and odds of weight loss of ≥ 1 kg during study (OR)
Effect size 95% confidence limits p value
HbA1c (%) [mmol/mol]*
Primary care vs. specialist care 0.04 [0.4] 0.09 to +0.01 [1.0, +0.1] 0.1590
Insulin dose (U/kg)†
Primary care vs. specialist care +0.06 +0.06 to +0.07 < 0.0001
Hypoglycaemia event (OR)*
Primary care vs. specialist care 0.75 0.64–0.87 0.0002
Weight loss ≥ 1 kg (OR)‡
Primary care vs. specialist care 1.07 0.98–1.16 0.1409
*Adjusted for age category (< 50 years, 50–75 years in 5-year intervals and ≥ 75 years), diabetes duration (in quartiles), BMI
category (< 25 kg/m2, 25 to < 30 kg/m2, 30 to < 35 kg/m2 and ≥ 35 kg/m2), previous history of hypoglycaemia or microvascular
disease, number and change in OAD therapy at the time of insulin initiation, HbA1c at baseline and insulin dose (U in quartiles).
†Adjusted for diabetes duration and weight at baseline. ‡Adjusted for gender, BMI (as presented above), number of OADs at baseline
and baseline HbA1c. BMI, body mass index; HbA1c, glycated haemoglobin.
Table 4 Number and type of concomitant OAD, lipid-lowering and antihypertensive treatment at final visit, according
to healthcare provider group
Cohort
p valuePrimary care Specialist care
Number of OADs (%)
1 2119 (60.7) 4031 (36.1) < 0.0001
2 1178 (33.8) 5875 (52.7)
> 2 152 (4.4) 1206 (10.8)
Types of OADs (%)
Biguanide 2889 (83.8) 8651 (77.9) < 0.0001
Sulphonylureas 970 (28.1) 5413 (48.7) < 0.0001
Glinides 332 (9.6) 2468 (22.2) < 0.0001
a-glucosidase inhibitor 60 (1.7) 1726 (15.5) < 0.0001
Thiazolidinediones 152 (4.4) 976 (8.8) < 0.0001
Dipeptidyl-peptidase IV inhibitors 528 (15.3) 249 (2.2) < 0.0001
Any lipid-lowering drug treatment 1543 (61.2) 4321 (43.2) < 0.0001
Any antihypertensive drug treatment 2321 (78.1) 6590 (60.0) < 0.0001
OAD, oral antidiabetic drug.
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greater number of dose adjustments in the primary
care compared with the specialist care group
(4.8  7.5 vs. 2.6  3.6 dose adjustments at the
interim visit, respectively, and 2.9  5.0 vs.
1.9  2.5 dose adjustments at the final visit, respec-
tively, p < 0.0001).
Discussion
This subanalysis of a large, international, observa-
tional study showed several baseline demographic
differences between patients who were initiating basal
insulin therapy in primary and specialist care, partic-
ularly with respect to weight and the number and
type of OADs prescribed. Patients managed by spe-
cialists were younger and leaner and had fewer
macrovascular complications, but a longer duration
of OAD treatment. Although it is clear that patients
are different in primary care and specialised care,
these possible confounders could be adjusted by
statistics analysis.
Glycaemic control, insulin doses, weight and
hypoglycaemia during the study
There were no significant effects of HCP type on
glycaemic control and weight loss ≥ 1 kg, despite a
statistically significant but clinically small increase in
insulin dose in the primary care group of patients.
After adjustment for known confounders, the risk of
at least one hypoglycaemic episode was significantly
higher in patients who were managed in specialist
care.
The higher risk of minor hypoglycaemia in the
specialist care group may reflect differences in the
case mix between the two HCP groups—the more
complex and difficult-to-treat patients are managed
by specialists rather than primary care practitioners
(i.e. confounding by indication) (5,16–19). Weight,
which is known to be protective of insulin-induced
hypoglycaemia (20), was significantly lower in the
group receiving specialist care. The higher propor-
tion of patients continuing to use oral agents such
as sulphonylureas and glinides, which are known
to be associated with a higher risk of hypogly-
caemia relative to other oral agents, may have been
a contributing factor in the group receiving
specialist care.
OAD management following insulin initiation
When the individual classes of OADs were examined,
it was found that patients managed by specialists
were using fewer DPP-IV inhibitors and more
sulphonylureas, glinides and a-glucosidase inhibitors.
As in specialist care insulin was prescribed most
commonly in addition to at least two oral agents, it
was more likely that patients would receive drugs
other than biguanides. In the present study, the use
of DPP-IV inhibitors was higher in the primary care
group. These numbers may indicate differences in
availability and reimbursement of DPP-IV inhibitors
between participating countries, but they may also
indicate that primary care providers tend to use
agents with perceived lower hypoglycaemia risk and/
or are quicker to adopt novel treatments than previ-
ously reported (21,22).
Patients in the specialised care group had a longer
duration of OAD therapy and higher use of secreta-
gogues, which are known to have higher monother-
apy failure rates (23,24). Perhaps, these patients are
also more likely to be referred to a specialist by pri-
mary care physicians who do not usually prescribe
insulin. However, the level of glycaemic control
achieved by both the primary and specialist care
groups was similar at the final visit, and insulin
doses were lower in the group of patients managed
by specialist care. In addition, the effects of individ-
ual oral agents were not included in regression
models.
Physician resource utilisation
The management of diabetes is associated with an
increase in healthcare resources that may begin
24 months before the diagnosis (2). In the present
study, primary care allowed more time to train
patients, and there was also evidence of more fre-
quent face-to-face contact with patients in the group
managed by primary care compared with specialist
care. These factors may have contributed to a greater
number of dose adjustments in the primary care
group. As in the present study, Harris et al. (11)
reported higher basal insulin analogue doses in
patients managed in primary care compared with
those patients managed by specialists, but there was
a higher concomitant use of OADs among patients
managed by specialists.
Although follow-up has been shown to be better
in specialist clinics compared with primary care (18),
other authors reported that specialist care did not
improve survival in adults with diabetes cared for in
ambulatory care settings (25). McAlister’s study
cohort (1991–2001) predates the Action to Control
Cardiovascular Risk in Diabetes study, which also
reported a survival disadvantage in patients receiving
intensive glycaemic [mean HbA1c 6.4% (46 mmol/
mol)] vs. standard glycaemic [mean HbA1c 7.5%
(58 mmol/mol)] control (26).
In addition, there have been continual improve-
ments in the primary care management of type 2
diabetes. In Spain, for example, primary care cen-
tres, which are similar to those participating in the
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present study, demonstrated significant improve-
ments between 1993 and 2007 in process measures
(such as measurement of HbA1c and lipid levels),
intermediate outcome measures [including the pro-
portion of patients with HbA1c ≤7.0% (53 mmol/
mol), total cholesterol ≤ 200 mg/dl and blood
pressure ≤ 140/90 mmHg], and microvascular com-
plications (27,28). Primary care–led structured care,
with relatively limited but well-focussed investment,
can achieve quality of care for patients with dia-
betes, comparable to international best practice (7).
The organisation of primary care service provision
for diabetes continues to evolve. Structured care
with computerised central recall systems, which
have been shown to achieve standards of care that
are equivalent to, or better than, hospital outpa-
tient care (29,30), are gradually replacing unstruc-
tured community-based care by individual primary
care physicians (31). However, there have been no
improvements in biomedical outcomes as a result
of structured care (32–34), and a significant pro-
portion of patients with type 2 diabetes probably
still underuse healthcare services (35). Also, to
improve access to specialists for new patients, an
efficient and appropriate discharge process is
required. It is important to prepare patients for
discharge from care and to recognise that individ-
ual patients have varying needs and preferences
(36).
Thus, whether or not specialists are more likely to
implement processes of care, these differences are
generally small compared with the overall deficiencies
in the quality of healthcare provision (37). Therefore,
future research should instead focus on ways to
implement high quality care, regardless of type of
HCP.
Limitations
There are important limitations to this study. As this
was an observational study, any differences between
the primary care and specialist care groups may be
the result of unmeasured confounding variables. The
effect of HCP type on HbA1c, hypoglycaemia and
weight was examined using regression analyses
including several known confounders. However, four
out of five of the largest-recruiting countries were
managed entirely by specialist care physicians, and
this constitutes a selection bias. It is uncertain how
these differences in the involvement of primary and
specialist care in each of the participating countries
would influence the results of this analysis. Because
the interaction between primary and specialist care
tends to be specific to each country, it will be
important to validate the results reported here in
each individual country.
More effective collaboration between primary and
specialist caregivers is still required to avoid delays in
appropriate treatment intensification (9,38). Better
collaboration between primary and specialist care-
givers (e.g. facilitating interactive communication
and the use of interdisciplinary diabetes care teams)
is considered to be one of the most important ways
to improve insulin treatment in patients with type 2
diabetes (39–41).
In summary, we showed similar glycaemic control
without increased risk of hypoglycaemia following ini-
tiation of basal insulin analogue treatment in patients
managed in primary care compared with specialist
care, which provides strong reassurance that the tran-
sition of insulin initiation from specialist to primary
care has been successful. Primary care is a necessary
and able partner in providing type 2 diabetes care.
Future research should focus on ways to facilitate col-
laboration between primary and specialist caregivers.
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